Olympia Pharmaceuticals Announces the Launch of Sister Brand, Wesley Pharmaceuticals, in Honor of Beloved Employee
18. Dezember 2024 10:05 ET
|
Olympia Pharmaceuticals
ORLANDO, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals, a leading innovator in the pharmaceutical industry, is proud to announce the launch of its new sister brand: Wesley...
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
17. Dezember 2024 06:30 ET
|
Silexion Therapeutics Corp
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
[Latest] Global Dry Eye Syndrome Treatment Market Size/Share Worth USD 12,281.4 Million by 2033 at a 7.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
11. Dezember 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Dry Eye Syndrome Treatment Market Size, Trends and Insights By Type (Evaporative...
Inflation Reduction Act Likely to Shape Specialty Prescribing Decisions in 2025, According to Spherix Global Insights
10. Dezember 2024 09:59 ET
|
Spherix Global Insights
EXTON, PA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- In 2022, the U.S. Congress enacted the Inflation Reduction Act (IRA), a landmark piece of legislation aimed at addressing various national priorities,...
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
10. Dezember 2024 08:30 ET
|
Silexion Therapeutics Corp
Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
10. Dezember 2024 07:00 ET
|
Relation Therapeutics
FOR IMMEDIATE RELEASERelation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis London, UK, December 10, 2024 – Relation, an industry...
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
10. Dezember 2024 02:00 ET
|
Relation Therapeutics
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis London, UK, December 10, 2024 – Relation, an industry leader in deploying...
Bionical Emas sells EMAS Pharma to Kester Capital following strategic review
09. Dezember 2024 02:00 ET
|
Bionical Emas
Bionical Emas, the Early Access Programs and Clinical Trial Supply business, is selling EMAS Pharma to Kester Capital and an incoming executive team.
Kester Capital backs experienced management team in acquiring EMAS Pharma
09. Dezember 2024 02:00 ET
|
EMAS Pharma
Kester Capital, alongside a new senior management team, has acquired EMAS Pharma, the clinical development division of Bionical Emas.
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
22. November 2024 16:30 ET
|
Silexion Therapeutics Corp
GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...